Department of Animal Medicine and Surgery, Veterinary School, RegionalCampus of International Excellence Campus Mare Nostrum, University of Murcia, 30100, Murcia, Spain.
BMC Vet Res. 2012 Aug 28;8:147. doi: 10.1186/1746-6148-8-147.
Recently, metabolic syndrome (MS) has gained attention in human metabolic medicine given its associations with development of type 2 diabetes mellitus and cardiovascular disease. Canine obesity is associated with the development of insulin resistance, dyslipidaemia, and mild hypertension, but the authors are not aware of any existing studies examining the existence or prevalence of MS in obese dogs.Thirty-five obese dogs were assessed before and after weight loss (median percentage loss 29%, range 10-44%). The diagnostic criteria of the International Diabetes Federation were modified in order to define canine obesity-related metabolic dysfunction (ORMD), which included a measure of adiposity (using a 9-point body condition score [BCS]), systolic blood pressure, fasting plasma cholesterol, plasma triglyceride, and fasting plasma glucose. By way of comparison, total body fat mass was measured by dual-energy X-ray absorptiometry, whilst total adiponectin, fasting insulin, and high-sensitivity C-reactive protein (hsCRP) were measured using validated assays.
Systolic blood pressure (P = 0.008), cholesterol (P = 0.003), triglyceride (P = 0.018), and fasting insulin (P < 0.001) all decreased after weight loss, whilst plasma total adiponectin increased (P = 0.001). However, hsCRP did not change with weight loss. Prior to weight loss, 7 dogs were defined as having ORMD, and there was no difference in total fat mass between these dogs and those who did not meet the criteria for ORMD. However, plasma adiponectin concentration was less (P = 0.031), and plasma insulin concentration was greater (P = 0.030) in ORMD dogs.
In this study, approximately 20% of obese dogs suffer from ORMD, and this is characterized by hypoadiponectinaemia and hyperinsulinaemia. These studies can form the basis of further investigations to determine path genetic mechanisms and the health significance for dogs, in terms of disease associations and outcomes of weight loss.
最近，代谢综合征（MS）因其与 2 型糖尿病和心血管疾病的发展有关，在人类代谢医学中受到关注。犬肥胖与胰岛素抵抗、血脂异常和轻度高血压的发展有关，但作者不知道有任何现有的研究检查肥胖犬中 MS 的存在或流行情况。35 只肥胖犬在减肥前后进行了评估（中位数百分比下降 29%，范围 10-44%）。为了定义与犬肥胖相关的代谢功能障碍（ORMD），修改了国际糖尿病联合会的诊断标准，其中包括肥胖程度的衡量标准（使用 9 分身体状况评分[BCS]）、收缩压、空腹血浆胆固醇、血浆甘油三酯和空腹血糖。作为比较，使用双能 X 射线吸收法测量全身脂肪量，而使用经过验证的测定法测量总脂联素、空腹胰岛素和高敏 C 反应蛋白（hsCRP）。
减肥后收缩压（P=0.008）、胆固醇（P=0.003）、甘油三酯（P=0.018）和空腹胰岛素（P<0.001）均降低，而血浆总脂联素增加（P=0.001）。然而，hsCRP 随体重减轻而不变。在减肥前，有 7 只狗被定义为患有 ORMD，这些狗与不符合 ORMD 标准的狗之间的总脂肪量没有差异。然而，ORMD 狗的血浆脂联素浓度较低（P=0.031），血浆胰岛素浓度较高（P=0.030）。
在这项研究中，大约 20%的肥胖犬患有 ORMD，其特征是脂联素减少和胰岛素升高。这些研究可以为进一步研究奠定基础，以确定与疾病关联和减肥结果相关的犬的遗传机制和健康意义。
